Stock Events

Stock Events

Biocryst Pharmaceuticals 

$9.96
160
-$0.13-1.29% Friday 20:00
+$0.10+1%Friday 23:48After hours

Statistics

Day High
9.96
Day Low
9.95
52W High
11.22
52W Low
6
Volume
46,098
Avg. Volume
-
Mkt Cap
2.55B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.98
-1.89
-0.79
0.3
Expected EPS
0.093424
Actual EPS
N/A

Financials

30.16%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
874.84MRevenue
263.86MNet Income

Analyst Ratings

21.57Average Price Target
The highest estimate is 32.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
71%
Hold
29%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCRX. It's not an investment recommendation.
Apple
31
AAPL
Tesla
26
TSLA
Amazon
26
AMZN
NVIDIA
25
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Biocryst's focus on rare diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals competes in the rare disease space with its RNAi therapeutics, overlapping with Biocryst's target market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing and commercializing treatments for rare diseases, among other areas, making it a competitor.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences operates in the development of antiviral drugs for infections like HIV, hepatitis, and influenza, competing with Biocryst's antiviral programs.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for rare diseases, which puts it in competition with Biocryst.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, directly competing with Biocryst's rare disease portfolio.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a leading company in diabetes care but also ventures into rare blood disorders, making it a competitor in the rare disease market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio including treatments for rare diseases and a strong focus on research and development, competing across several of Biocryst's areas of interest.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diverse biopharmaceutical portfolio, including treatments for rare diseases, competing with Biocryst in the biotech and pharmaceutical market.

About

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Show more...
CEO
Charles K. Gayer
Employees
435
Country
United States
ISIN
US09058V1035
WKN
000896047

Listings

MU
DE
BO1.MU
STU
DE
BO1.STU
F
DE
BO1.F
XNAS
US
BCRX

0 Comments

Share your thoughts

FAQ

What is Biocryst Pharmaceuticals stock price today?▼
The current price of BCRX is $9.96 USD — it has decreased by -1.29% in the past 24 hours. Watch Biocryst Pharmaceuticals stock price performance more closely on the chart.
What is Biocryst Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Biocryst Pharmaceuticals stocks are traded under the ticker BCRX.
Is Biocryst Pharmaceuticals stock price growing?▼
BCRX stock has risen by +1.43% compared to the previous week, the month change is a +9.81% rise, over the last year Biocryst Pharmaceuticals has showed a +20.44% increase.
What is Biocryst Pharmaceuticals market cap?▼
Today Biocryst Pharmaceuticals has the market capitalization of 2.55B
When is the next Biocryst Pharmaceuticals earnings date?▼
Biocryst Pharmaceuticals is going to release the next earnings report on November 04, 2026.
What were Biocryst Pharmaceuticals earnings last quarter?▼
BCRX earnings for the last quarter are 0.3 USD per share, whereas the estimation was 0.15 USD resulting in a +94.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biocryst Pharmaceuticals revenue for the last year?▼
Biocryst Pharmaceuticals revenue for the last year amounts to 874.84M USD.
What is Biocryst Pharmaceuticals net income for the last year?▼
BCRX net income for the last year is 263.86M USD.
How many employees does Biocryst Pharmaceuticals have?▼
As of September 05, 2026, the company has 435 employees.
In which sector is Biocryst Pharmaceuticals located?▼
Biocryst Pharmaceuticals operates in the Health & Wellness sector.
When did Biocryst Pharmaceuticals complete a stock split?▼
Biocryst Pharmaceuticals has not had any recent stock splits.
Where is Biocryst Pharmaceuticals headquartered?▼
Biocryst Pharmaceuticals is headquartered in DURHAM, United States.